A new algorithm-based surveillance test for ovarian cancer is being offered on the NHS to women carrying BRCA1 or BRCA2 mutations...
A 'multiomic' test could detect biological differences between patients with and without ovarian cancer...
Four stranded regions of the genome have been linked to chemotherapy resistance in ovarian cancer, offering a new potential avenue for therapy...
'Established in 2007, in a gale of publicity, 23andMe benefitted from the valetudinarian personal genetic healthcare imaginary that appeared in the wake of the Human Genome Project,' writes Dr Pete Mills, as he documents the rise and fall of 23andMe...
The British health insurance and healthcare company Bupa plans to offer an approach to people's genomic data that, it is claimed, can evaluate an individual's risk of developing seven common diseases...
The effectiveness of radiotherapy in killing cancer cells depends on the DNA repair pathway the cell uses to fix radiation-induced damage...
Over 3000 genetic variants could disrupt normal function of the RAD51C breast and ovarian cancer gene...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.
